Hikma Pharmaceuticals USA Inc., et al., Petitioners v. Amarin Pharma, Inc., et al.

Hikma Pharmaceuticals wants to sell a generic version of the heart drug Vascepa for a specific use that is no longer protected by a patent. Amarin Pharma, the maker of the brand-name drug, argues that Hikma is illegally encouraging doctors to use the generic for a different, still-patented use. The Court will decide if a generic company is liable for patent infringement if its label excludes the patented use but it still calls itself a generic version.

This case could determine how easily generic drug companies can enter the market to provide lower-cost alternatives. If the Court rules against Hikma, it might become harder for patients to access cheaper versions of expensive branded medications. This affects anyone who relies on affordable drugs to treat chronic conditions like heart disease.

The legal system tries to balance protecting the inventions of drug companies with the public's need for affordable medicine. This case focuses on 'skinny labeling,' where generic makers only list non-patented uses to avoid legal trouble. The outcome will clarify the rules for how these companies can describe their products without violating existing patents.

No substantive justice or advocate reactions are available yet.

The Supreme Court must decide if a generic drug maker 'induces' patent infringement simply by calling its product a generic version of a brand-name drug.

The Supreme Court has agreed to hear the case, but a date for oral arguments has not yet been scheduled. After the arguments take place, the justices will likely release a final decision by the end of their term in June.

Induced infringement happens when one company encourages another person or company to violate a patent. In this case, Amarin claims Hikma's marketing encourages doctors to prescribe the generic for patented uses even if the label does not mention them.

A skinny label allows a generic company to sell a drug only for medical uses that are not protected by patents. This helps them get cheaper drugs to market faster while technically avoiding the brand-name company's legal rights to other uses.

The case involves the drug Vascepa, which is used to treat very high triglyceride levels and reduce cardiovascular risks. Hikma wants to sell a generic version for the triglyceride treatment while avoiding the patent on the cardiovascular risk reduction use.

Amarin argues that by calling its product a generic version of Vascepa, Hikma is implying it can be used for everything the brand-name drug does. This includes the cardiovascular uses that Amarin still holds a valid patent for.

The next major milestone will be the oral argument, where lawyers for both pharmaceutical companies present their cases to the justices. After that, the Court will meet privately to vote and begin writing their opinions.